Read your latest personalised notifications
No account yet? Start here
Don't miss out
Ok, got it
EUROASPIRE V is the latest in a series of cross-sectional surveys carried out under the auspices of the ESC EURObservational Research Programme. As in previous surveys, EUROASPIRE V focuses on two groups of patients: hospital patients with coronary heart disease and apparently healthy individuals in primary care at high risk of developing cardiovascular disease (CVD).
Professor Kornelia Kotseva, Scientific Steering Committee Chair of EUROASPIRE V, provided an update on the latest findings. “One of the main aims of EUROASPIRE is to see if ESC Guidelines on CVD prevention are being followed. We recently published an analysis of the hospital arm of EUROASPIRE V in European Journal of Preventive Cardiology, which showed that lifestyle and risk factor management in patients with coronary heart disease are still far from optimal.1 We interviewed 8,261 coronary patients from 131 centres in 27 countries and found that the majority had unhealthy lifestyles in terms of smoking, diet and sedentary behaviour. Also, the majority did not achieve their blood pressure, lipid and glycaemic targets in line with ESC 2016 Guidelines, although the use of cardioprotective medications was high.”
Prof. Kotseva continued, “We presented initial results from the primary care arm of EUROASPIRE V at the World Congress of Cardiology & Cardiovascular Health in December 2018.2 Risk factor management was also disappointing in individuals at high risk of CVD. In 2,759 participants from 16 countries, we found that 37% were overweight, 44% were obese and 64% centrally obese. Nearly one in five participants were smokers and just 36% achieved the recommended physical activity levels.
At EuroPrevent 2019, I will present new data from the primary care arm, which will look at temporal trends, comparing results from EUROASPIRE V with the previous EUROASPIRE IV survey.”
“It is clear,” she concluded, “that we need some urgent effective preventive cardiology programmes both for patients with established coronary disease and those at high CVD risk, which focus on all aspects of lifestyle and risk factor management in order to reduce their risk of future CVD events.”
Results from EUROASPIRE V and more will be presented at the symposium entitled ‘Guidelines, clinical evidence and real life practice: How to find your way in managing patients at high cardiovascular risk?’
Thursday: 11:00 – 12:30; Faro
Our mission: To reduce the burden of cardiovascular disease.
© 2020 European Society of Cardiology. All rights reserved.